Blink Biomedical

Antibody-based checkpoint inhibitors for oncology.

placeLyon, Auvergne Rhone Alpes, France calendar_todayFounded 2015 groups11 employees language blinkbiomedical.com

Innovation

5 patent families (2 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 228 times.

YearFilings
20161
20171
20181
20192
20203
20221
20232
20251

Investor mix

2 investors on record; lead investors include Idinvest Partners.

Investor typeCountShare
Venture capital150%
Private equity150%
Coming soon